REVENUES (Tables)

6 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Revenues were as follows:


	Three Months Ended June 30, 2021								Three Months Ended June 30, 2020
(in millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product Sales:
HIV
Atripla	$	52	$	4	$	4	$	60	$	95	$	5	$	3	$	103
Biktarvy	1,586		237		171		1,994		1,350		153		101		1,604
Complera/Eviplera	20		39		3		62		27		42		3		72
Descovy	357		44		34		435		337		46		34		417
Genvoya	551		100		55		706		646		109		61		816
Odefsey	258		111		13		382		273		98		11		382
Stribild	35		11		5		51		39		12		8		59
Truvada	94		6		8		108		370		6		11		387
Other HIV(1)	5		4		2		11		11		1		16		28
Revenue share - Symtuza(2)	86		40		3		129		90		40		2		132
Total HIV	3,044		596		298		3,938		3,238		512		250		4,000
Hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3)	30		3		29		62		24		4		39		67
Sofosbuvir/Velpatasvir(4)	262		82		98		442		165		57		113		335
Other HCV(5)	35		8		2		45		31		9		6		46
Total HCV	327		93		129		549		220		70		158		448
Hepatitis B virus (“HBV”) / Hepatitis Delta virus (“HDV”)
Vemlidy	86		8		106		200		76		7		68		151
Viread	3		8		17		28		3		8		54		65
Other HBV/HDV(6)	1		8		—		9		1		2		—		3
Total HBV/HDV	90		24		123		237		80		17		122		219

Veklury	416		264		149		829		—		—		—		—

Cell Therapy
Tecartus	32		9		—		41		—		1		—		1
Yescarta	108		61		9		178		95		56		5		156
Total Cell Therapy	140		70		9		219		95		57		5		157

Trodelvy	89		—		—		89		—		—		—		—
Other
AmBisome	13		69		74		156		10		49		36		95
Letairis	57		—		—		57		80		—		—		80
Ranexa	2		—		—		2		1		—		—		1
Zydelig	8		13		1		22		8		9		1		18
Other(7)	27		18		9		54		38		10		1		49
Total Other	107		100		84		291		137		68		38		243
Total product sales	4,213		1,147		792		6,152		3,770		724		573		5,067
Royalty, contract and other revenues	20		45		—		65		14		62		—		76
Total revenues	$	4,233	$	1,192	$	792	$	6,217	$	3,784	$	786	$	573	$	5,143


	Six Months Ended June 30, 2021								Six Months Ended June 30, 2020
(in millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product Sales:
HIV
Atripla	$	75	$	8	$	8	$	91	$	176	$	12	$	10	$	198
Biktarvy	3,051		453		314		3,818		2,762		334		201		3,297
Complera/Eviplera	45		73		7		125		51		89		8		148
Descovy	639		86		69		794		700		107		68		875
Genvoya	1,057		206		116		1,379		1,258		260		122		1,640
Odefsey	498		224		27		749		542		225		24		791
Stribild	66		22		9		97		73		29		10		112
Truvada	213		13		17		243		753		14		26		793
Other HIV(1)	11		5		12		28		14		3		19		36
Revenue share - Symtuza(2)	175		84		5		264		162		78		4		244
Total HIV	5,830		1,174		584		7,588		6,491		1,151		492		8,134
HCV
Ledipasvir/Sofosbuvir(3)	49		19		50		118		77		15		87		179
Sofosbuvir/Velpatasvir(4)	476		157		190		823		476		179		244		899
Other HCV(5)	60		52		6		118		65		24		10		99
Total HCV	585		228		246		1,059		618		218		341		1,177
HBV / HDV
Vemlidy	163		16		202		381		149		14		124		287
Viread	7		15		37		59		7		19		79		105
Other HBV/HDV(6)	1		16		—		17		9		4		—		13
Total HBV/HDV	171		47		239		457		165		37		203		405

Veklury	1,236		652		397		2,285		—		—		—		—

Cell Therapy
Tecartus	59		13		—		72		—		1		—		1
Yescarta	200		122		16		338		198		93		5		296
Total Cell Therapy	259		135		16		410		198		94		5		297

Trodelvy	161		—		—		161		—		—		—		—
Other
AmBisome	25		135		117		277		28		108		78		214
Letairis	111		—		—		111		163		—		—		163
Ranexa	5		—		—		5		9		—		—		9
Zydelig	16		20		1		37		16		21		1		38
Other(7)	54		31		17		102		71		22		4		97
Total Other	211		186		135		532		287		151		83		521
Total product sales	8,453		2,422		1,617		12,492		7,759		1,651		1,124		10,534
Royalty, contract and other revenues	40		106		2		148		31		110		16		157
Total revenues	$	8,493	$	2,528	$	1,619	$	12,640	$	7,790	$	1,761	$	1,140	$	10,691

_______________________________

(1) Includes Emtriva and Tybost.

(2) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5) Includes Vosevi and Sovaldi.

(6) Includes Hepcludex and Hepsera.

(7) Includes Cayston and Jyseleca.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
(as a percentage of total revenues)	2021		2020		2021		2020
AmerisourceBergen Corporation	21	%	21	%	24	%	21	%
Cardinal Health, Inc.	23	%	23	%	21	%	23	%
McKesson Corporation	17	%	23	%	17	%	22	%